FENC Fennec Pharmaceuticals Inc.
Legal ·
Under a license agreement, the lawsuit will be dismissed and Cipla will not sell a generic version in the U.S. until September 1, 2033, or earlier under specified circumstances. Each side bears its own costs.
The payment to Petrichor comes from available cash. It cuts about $1.5 million in annual interest and removes about 1.6 million potential shares.
Fennec Pharmaceuticals is a biopharmaceutical company that describes itself as a single product company, with PEDMARK as its only product. PEDMARK has received marketing approval from the U.S. Food and Drug Administration and from the European Commission, but not from any other foreign authorities. The company says it has only recently transitioned from a development stage biopharmaceutical company to a commercial stage company, and it reports a history of significant losses and limited revenue from product sales. Its strategy depends in part on third-party development partners that seek approvals and commercialize PEDMARK outside the United States: Norgine Pharma UK Limited in Europe, and Inpharmus, formerly TRPharm, in Turkey and Gulf Cooperation Council countries. The company says PEDMARK targets diseases with small patient populations. It relies on third parties to supply raw materials, conduct clinical trials and manufacture PEDMARK, and it notes that it may be required to conduct additional clinical trials for PEDMARK. The company also holds orphan drug exclusivity considerations under review by regulators.
| Product or program | What it is | Stage |
|---|---|---|
| PEDMARK | Only product; targets diseases with small patient populations | Approved by the FDA and the European Commission |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $44.6 million | $47.5 million |
| Research and development | $250,000 | $307,000 |
| Net income (loss) | -$9.7 million | -$436,000 |
| Cash from operations | -$12.5 million | $27.0 million |
| Cash and equivalents | $36.8 million | $26.6 million |
Our latest story on this, dated Dec 20, 2024: "Fennec Pharmaceuticals repays $13 million of convertible debt early". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 16, 2026: "Fennec Pharmaceuticals settles PEDMARK patent litigation with Cipla". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 16, 2026: "Fennec Pharmaceuticals settles PEDMARK patent litigation with Cipla". The story links the filing or release it is based on. Read the story.
Fennec Pharmaceuticals Inc. trades under the ticker FENC on NASDAQ.
Fennec Pharmaceuticals Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:RV41; LS:A12A5F; TSX:FRX.
The SEC Central Index Key (CIK) for Fennec Pharmaceuticals Inc. is 1211583. Its filings are on SEC EDGAR.
35,067,159 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Fennec Pharmaceuticals Inc. under United States.
Our directory classifies Fennec Pharmaceuticals Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Fennec Pharmaceuticals Inc. is CA31447P1009.
aibio.space lists Fennec Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A1.
Fennec Pharmaceuticals is a biopharmaceutical company that describes itself as a single product company, with PEDMARK as its only product. PEDMARK has received marketing approval from the U.S. Food and Drug Administration and from the European Commission, but not from any other foreign authorities.
PEDMARK: Only product; targets diseases with small patient populations Stage: Approved by the FDA and the European Commission.
$44.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio